Bio-Rad Laboratories Hits New 52-Week High of $355.09

Bio-Rad Laboratories, Inc. has reached a significant milestone by hitting a new 52-week high of USD 355.09 on August 10, 2026. This achievement underscores the company's strong performance within the Pharmaceuticals & Biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 7,235 million. Over the past year, Bio-Rad has demonstrated a robust performance, with a 24.64% increase, outpacing the S&P 500's growth of 21.34%. The company's price-to-earnings (P/E) ratio stands at 21.00, reflecting its valuation relative to earnings. Additionally, Bio-Rad's price-to-book ratio is 0.97, indicating a favorable valuation compared to its book value. Despite a dividend yield of 0.00%, the company maintains a solid financial position with a debt-to-equity ratio of -0.04 and a return on equity of 4.65%. The stock's previous 52-week low was recorded at USD 239, highlighting the significant upward movement in its price. This new high marks an important moment for Bio-Rad Laboratories as it continues to navigate the competitive landscape of its industry.